Your browser doesn't support javascript.
loading
Isoniazid and rifampicin exposure during treatment in drug-susceptible TB.
Akkerman, O W; Dijkwel, R D C; Kerstjens, H A M; van der Werf, T S; Srivastava, S; Sturkenboom, M G G; Bolhuis, M S.
  • Akkerman OW; Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, Tuberculosis Center Beatrixoord, University of Groningen, University Medical Center Groningen, Haren.
  • Dijkwel RDC; Departments of Clinical Pharmacy and Pharmacology, and.
  • Kerstjens HAM; Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen.
  • van der Werf TS; Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, Departments of Internal Medicine and Infectiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Srivastava S; Department of Medicine, The University of Texas Health Science Center at Tyler, Tyler, TX, USA, Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX, USA, Department of Center for Biomedical Research, The University of Texas Health Science C
  • Sturkenboom MGG; Departments of Clinical Pharmacy and Pharmacology, and.
  • Bolhuis MS; Departments of Clinical Pharmacy and Pharmacology, and.
Int J Tuberc Lung Dis ; 27(10): 772-777, 2023 10 01.
Article en En | MEDLINE | ID: mdl-37749836
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis / Isoniazida Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis / Isoniazida Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article